ArticleDiscover oncology2026
Feasibility of an oral hydration regimen post high-dose methotrexate in children with acute leukemia: a pilot study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdministration of high-dose methotrexate(HDMTX) requires strict intravenous hydration contributing to lengthy hospital stays. Transition to oral hydration regimen(OHR) after ensuring adequate methotrexate(MTX) clearance could decrease duration of hospitalization. PURPOSE: The primary objective was to assess the feasibility of administration of OHR post HDMTX infusion in an in-hospital setting by evaluating the proportion of HDMTX courses completed on OHR.
methodsThis was a prospective, single-centre pilot study. Children with acute lymphoblastic leukemia/lymphoma aged 5-18years, treated on IciCLe-ALL-14 protocol were eligible. Following mandatory intravenous hydration phase and 24 h MTX level < 150micromol/L, children were started on OHR that included: (i) oral fluids, (ii) oral bicarbonate (650 mg/m2/dose q6h, tablet strength 500 mg) (iii) oral leucovorin(as per IciCLe-ALL-14 protocol, tablet strength 15 mg). Oral fluid intake and urine output were documented by parents, adherence was monitored periodically by nurses. 42 h MTX levels were measured. To ensure safety, children were changed to intravenous hydration if pre-defined clinical and laboratory withdrawal criteria were met.
resultsA total of 22 HDMTX courses of 13 participants were enrolled and 20 out of 22 (90.9%) HDMTX courses were completed on OHR. All, but two withdrawn courses, had a 42 h methotrexate < 1.0µmol/L. Withdrawals were due to inadequate urinary alkalinization with oral bicarbonate. Median oral hydration rate was 146.08ml/m2/h (Interquartile range, 60.01) against a minimum requirement of 125ml/m2/hr. No grade ¾ renal toxicity was observed. All courses with grade ½ vomiting achieved the required oral hydration rate and urine output. The median duration of oral hydration(OHd) was 25 h (Interquartile range, 2) in the in-patient setting.
conclusionOHR post HDMTX infusion is feasible in an in-patient setting in pediatric population with acute lymphoblastic leukemia/lymphoma. Early identification of criteria warranting withdrawal from OHR and reinstitution of intravenous hydration helps in mitigating severe effects of toxicity. The length of hospitalisation of a HDMTX course could be cut short by a duration of 25 h if implemented on outpatient basis. The study was approved by the Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi (IECPG-542/23.09.2021, RT-23/25.11.2021, OT-06/07.06.2023) and registered under Clinical Trials Registry – India (CTRI/2022/02/040229 dated 11.02.2022).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.